PUB MED Publications update 2023

1: Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts
I, Salvi M, Stan MN. Management of Thyroid Eye Disease: A Consensus Statement by
the American Thyroid Association and the European Thyroid Association. Thyroid.
2022 Dec;32(12):1439-1470. doi: 10.1089/thy.2022.0251. Epub 2022 Dec 8. PMID:
36480280.

2: Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts
I, Salvi M, Stan MN. Management of thyroid eye disease: a Consensus Statement by
the American Thyroid Association and the European Thyroid Association. Eur
Thyroid J. 2022 Dec 8;11(6):e220189. doi: 10.1530/ETJ-22-0189. PMID: 36479875;
PMCID: PMC9727317.

3: Sawicka-Gutaj N, Gruszczyński D, Zawalna N, Nijakowski K, Muller I, Karpiński
T, Salvi M, Ruchała M. Microbiota Alterations in Patients with Autoimmune
Thyroid Diseases: A Systematic Review. Int J Mol Sci. 2022 Nov 3;23(21):13450.
doi: 10.3390/ijms232113450. PMID: 36362236.

4: Barbesino G, Salvi M, Freitag SK. Future Projections in Thyroid Eye Disease.
J Clin Endocrinol Metab. 2022 Aug 8;107(Supplement_1):S47-S56. doi:
10.1210/clinem/dgac252. PMID: 36346684; PMCID: PMC9359449.

5: Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, Montacchini
B, Covelli D, Guastella C, Pignataro L, Fugazzola L, Arosio M, Salvi M. Therapy
With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-
Severe Graves' Orbitopathy. Front Endocrinol (Lausanne). 2022 Jan 25;12:790246.
doi: 10.3389/fendo.2021.790246. PMID: 35145479; PMCID: PMC8822584.

6: Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R,
Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M,
Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt
RJ, Smith TJ. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration
Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology. 2022
Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. PMID:
34688699.

7: Vannucchi G, Campi I, Covelli D, Currò N, Lazzaroni E, Palomba A, Soranna D,
Zambon A, Fugazzola L, Muller I, Guastella C, Salvi M. Efficacy Profile and
Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy. Thyroid.
2021 May;31(5):821-828. doi: 10.1089/thy.2020.0269. Epub 2021 Mar 31. Erratum
in: Thyroid. 2022 May;32(5):605. PMID: 33234032.

8: Campi I, Currò N, Vannucchi G, Covelli D, Simonetta S, Fugazzola L, Dazzi D,
Pignataro L, Guastella C, Lazzaroni E, Pirola G, Salvi M. Quantification of
Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle
Ductions. Thyroid. 2021 Feb;31(2):280-287. doi: 10.1089/thy.2020.0165. Epub 2020
Oct 22. PMID: 32940167.

9: Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A,
Ferrante E, Orsi E, Resi V, Longari V, Cuzzocrea M, Bandera A, Lazzaroni E,
Dolci A, Ceriotti F, Re TE, Gori A, Arosio M, Salvi M. SARS-CoV-2-related
atypical thyroiditis. Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741. doi:
10.1016/S2213-8587(20)30266-7. Epub 2020 Jul 30. PMID: 32738929; PMCID:
PMC7392564.

10: Žarković M, Wiersinga W, Perros P, Bartalena L, Donati S, Okosieme O, Morris
D, Fichter N, Lareida J, Daumerie C, Burlacu MC, Kahaly GJ, Pitz S, Beleslin B,
Ćirić J, Ayvaz G, Konuk O, Törüner FB, Salvi M, Covelli D, Curro N, Hegedüs L,
Brix T; EUGOGO (European Group on Graves’ Orbitopathy). Antithyroid drugs in
Graves' hyperthyroidism: differences between "block and replace" and "titration"
regimes in frequency of euthyroidism and Graves' orbitopathy during treatment. J
Endocrinol Invest. 2021 Feb;44(2):371-378. doi: 10.1007/s40618-020-01320-7. Epub
2020 Jun 10. PMID: 32524368.

11: Perros P, Žarković MP, Panagiotou GC, Azzolini C, Ayvaz G, Baldeschi L,
Bartalena L, Boschi AM, Nardi M, Brix TH, Covelli D, Daumerie C, Eckstein AK,
Fichter N, Ćirić S, Hegedüs L, Kahaly GJ, Konuk O, Lareida JJ, Okosieme OE, Leo
M, Mathiopoulou L, Clarke L, Menconi F, Morris DS, Orgiazzi J, Pitz S, Salvi M,
Muller I, Knežević M, Wiersinga WM, Currò N, Dayan CM, Marcocci C, Marinò M,
Möller L, Pearce SH, Törüner F, Bernard M; European Group on Graves’
Orbitopathy. Asymmetry indicates more severe and active disease in Graves'
orbitopathy: results from a prospective cross-sectional multicentre study. J
Endocrinol Invest. 2020 Dec;43(12):1717-1722. doi: 10.1007/s40618-020-01258-w.
Epub 2020 May 30. PMID: 32474767; PMCID: PMC7652741.

12: Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC,
Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A,
Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ,
Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J
Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. PMID: 31971679.

13: Vannucchi G, Covelli D, Campi I, Currò N, Dazzi D, Rodari M, Pepe G, Chiti
A, Guastella C, Lazzaroni E, Salvi M. Prevention of Orbitopathy by Oral or
Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients
Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.

Thyroid. 2019 Dec;29(12):1828-1833. doi: 10.1089/thy.2019.0150. PMID: 31860407.

14: Salvi M, Covelli D. Combined immunosuppressants and less steroids in active
graves' orbitopathy? Clin Endocrinol (Oxf). 2019 Apr;90(4):525-527. doi:
10.1111/cen.13917. Epub 2019 Jan 9. PMID: 30549306.

15: Salvi M, Covelli D. B cells in Graves' Orbitopathy: more than just a source
of antibodies? Eye (Lond). 2019 Feb;33(2):230-234. doi:
10.1038/s41433-018-0285-y. Epub 2018 Dec 4. PMID: 30514895; PMCID: PMC6367428.

16: Salvi M, Covelli D. Combined immunosuppressants and less steroids in active graves’ orbitopathy? Clin Endocrinol (Oxf). 2018 Dec 14. doi: 10.1111/cen.13917. [Epub ahead of print] PubMed PMID: 30549306.

17: Salvi M, Covelli D. B cells in Graves’ Orbitopathy: more than just a source of antibodies? Eye (Lond). 2019 Feb;33(2):230-234. doi: 10.1038/s41433-018-0285-y. Epub 2018 Dec 4. PubMed PMID: 30514895; PubMed Central PMCID: PMC6367428.

3: Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018 Nov 27;11:CD012984. doi: 10.1002/14651858.CD012984.pub2. Review. PubMed PMID: 30480323.

18: Salvi M. Step-down steroid-sparing therapy in active thyroid eye disease. Nat Rev Endocrinol. 2018 Nov;14(11):634-635. doi: 10.1038/s41574-018-0099-9. PubMed PMID: 30262854.

19: Zhang L, Masetti G, Colucci G, Salvi M, Covelli D, Eckstein A, Kaiser U, Draman MS, Muller I, Ludgate M, Lucini L, Biscarini F. Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves’ disease and orbitopathy. Sci Rep. 2018 May 30;8(1):8386. doi: 10.1038/s41598-018-26700-1. PubMed PMID: 29849043; PubMed Central PMCID: PMC5976672.

20: Wiersinga W, Žarković M, Bartalena L, Donati S, Perros P, Okosieme O, Morris D, Fichter N, Lareida J, von Arx G, Daumerie C, Burlacu MC, Kahaly G, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Törüner FB, Salvi M, Covelli D, Curro N, Hegedüs L, Brix T; EUGOGO (European Group on Graves’ Orbitopathy). Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol. 2018 Jun;178(6):635-643. doi: 10.1530/EJE-18-0039. Epub 2018 Apr 12. PubMed PMID:
29650691.

21: Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO). Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31. PubMed PMID: 29396246.

22: Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017 May 4;376(18):1748-1761.
doi: 10.1056/NEJMoa1614949. PubMed PMID: 28467880; PubMed Central PMCID: PMC5718164.

23: Stan MN, Salvi M. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves’ orbitopathy – lessons from randomized control trials. Eur J Endocrinol. 2017 Feb;176(2):R101-R109. Epub 2016 Oct 19. Review. PubMed PMID: 27760790.

24: Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C,Perros P, Salvi M, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2. PubMed PMID: 27099835;PubMed Central PMCID: PMC4836120.

25: Campi I, Vannucchi G, Salvi M. THERAPY OF ENDOCRINE DISEASE: EndocrineDilemma: Management of Graves’ Orbitopathy. Eur J Endocrinol. 2016 Mar 31. pii:EJE-15-1164. [Epub ahead of print] PubMed PMID: 27032693.

26: Salvi M, Campi I. Medical Treatment of Graves’ Orbitopathy. Horm Metab Res.2015 Sep;47(10):779-88. doi: 10.1055/s-0035-1554721. Epub 2015 Sep 11. PubMed
PMID: 26361263.

27: Perros P, Dayan CM, Dickinson AJ, Ezra DG, Hickey JL, Hintschisch C, Kahaly G,Lazarus JH, Ludgate M, Bartès B, MacEwen CJ, Mitchell AL, Morris D, O’Connor N,Pearce SH, Rose GE, Salvi M, Wiersinga WM, Williamson A; Thyroid Eye DiseaseAmsterdam Declaration Implementation Group UK; European Group on Graves’Orbitopathy. Future Research in Graves’ Orbitopathy: From Priority Setting toTrial Design Through Patient and Public Involvement. Thyroid. 2015 Nov;25(11):1181-4. doi: 10.1089/thy.2015.0222. Epub 2015 Oct 14. PubMed PMID:26359308; PubMed Central PMCID: PMC4652189.

28: Campi I, Tosi D, Rossi S, Vannucchi G, Covelli D, Colombo F, Trombetta E,Porretti L, Vicentini L, Cantoni G, Currò N, Beck-Peccoz P, Bulfamante G, Salvi M. B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases. Thyroid. 2015 Sep;25(9):1043-9. doi:
10.1089/thy.2015.0029. Epub 2015 Aug 13. PubMed PMID: 26214745.

29: Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A,Bournaud C, Brix TH, Covelli D, Ćirić S, Daumerie C, Eckstein A, Fichter N, Führer D, Hegedüs L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Currò N, Dayan C, Dickinson J,Knežević M, Lane C, Marcocci C, Marinò M, Möller L, Nardi M, Neoh C, Pearce S, von Arx G, Törüner FB. PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol. 2015 May 7. pii: bjophthalmol-2015-306733. doi: 10.1136/bjophthalmol-2015-306733. [Epub ahead of print] PubMed PMID: 25953846.

30: Covelli D, Vannucchi G, Campi I, Currò N, D’Ambrosio R, Maggioni M, Gianelli U, Beck-Peccoz P, Salvi M. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves’ orbitopathy. J Clin Endocrinol Metab. 2015 May;100(5):1731-7. doi: 10.1210/jc.2014-4463. Epub 2015 Mar 9. PubMed PMID: 25751109.

31: Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest. 2015 Feb 27. [Epub ahead of print] PubMed PMID: 25722226; PubMed Central PMCID: PMC4374116.

32: Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015 Feb;100(2):422-31. doi: 10.1210/jc.2014-3014. Epub 2014 Dec 15. PubMed PMID: 25494967; PubMed Central PMCID: PMC4318899.

33: Salvi M. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097. Review. PubMed PMID: 25105999.

34: Currò N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, Dazzi D, Guastella C, Pignataro L, Beck-Peccoz P, Ratiglia R, Salvi M. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014 May;24(5):897-905. doi: 10.1089/thy.2013.0445. Epub 2014 Mar 6. PubMed PMID: 24417307.

35: Vannucchi G, Covelli D, Campi I, Origo D, Currò N, Cirello V, Dazzi D, Beck-Peccoz P, Salvi M. The therapeutic outcome to intravenous steroid therapy for active Graves’ orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol. 2013 Nov 22;170(1):55-61. doi: 10.1530/EJE-13-0611. Print 2014 Jan. PubMed PMID: 24128430.

36: Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013 Nov;98(11):4291-9. doi: 10.1210/jc.2013-1804. Epub 2013 Sep 5. PubMed PMID: 24009135.

37: Campi I, Vannucchi GM, Minetti AM, Dazzi D, Avignone S, Covelli D, Currò N, Ratiglia R, Guastella C, Pignataro L, Beck-Peccoz P, Salvi M. A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves’ orbitopathy. Ophthalmology. 2013 May;120(5):1092-8. doi: 10.1016/j.ophtha.2012.10.041. Epub 2013 Feb 8. PubMed PMID: 23399378.

38: Vannucchi G, Campi I, Covelli D, Forzenigo L, Beck-Peccoz P, Salvi M. Treatment of pretibial myxedema with dexamethazone injected subcutaneously by mesotherapy needles. Thyroid. 2013 May;23(5):626-32. doi: 10.1089/thy.2012.0429. PubMed PMID: 23397966.

39: Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G; European Group on Graves’ Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63. doi: 10.1210/jc.2012-2389. Epub 2012 Oct 4. PubMed PMID: 23038682.

40: Vannucchi G, Covelli D, Currò N, Dazzi D, Maffini A, Campi I, Bonara P, Guastella C, Pignataro L, Ratiglia R, Beck-Peccoz P, Salvi M. Serum BAFF concentrations in patients with Graves’ disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab. 2012 May;97(5):E755-9. doi: 10.1210/jc.2011-2614. Epub 2012 Mar 7. PubMed PMID: 22399512.

41: Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012 Jan;130(1):122-4. doi: 10.1001/archopthalmol.2011.1215. PubMed PMID: 22232486.

42: Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Currò N, Simonetta S, Bonara P, Persani L, Guastella C, Wall J, Beck-Peccoz P, Salvi M. Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010 Sep;161(3):436-43. doi: 10.1111/j.1365-2249.2010.04191.x. PubMed PMID: 20529087; PubMed Central PMCID: PMC2962960.

43: Villani E, Viola F, Sala R, Salvi M, Mapelli C, Currò N, Vannucchi G, Beck-Peccoz P, Ratiglia R. Corneal involvement in Graves’ orbitopathy: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4574-8. doi: 10.1167/iovs.10-5380. Epub 2010 Apr 30. PubMed PMID: 20435595.

44: Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism. 2011 Feb;60(2):277-83. doi: 10.1016/j.metabol.2010.02.002. Epub 2010 Mar 6. PubMed PMID: 20206950.

45: Lazarus JH, Bartalena L, Marcocci C, Kahaly GJ, Krassas G, Wiersinga WM; EUGOGO (European Group on Graves’ Orbitopathy). Glucocorticoid administration for Graves’ hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. J Endocrinol Invest. 2010 Jun;33(6):409-13. doi: 10.3275/6794. Epub 2010 Jan 22. PubMed PMID: 20101098.

46: Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit. 2009;28(4):251-5. PubMed PMID: 19839884.

47: Vannucchi G, Campi I, Covelli D, Dazzi D, Currò N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009 Sep;94(9):3381-6. doi: 10.1210/jc.2009-0506. Epub 2009 Jun 30. PubMed PMID: 19567525.

48: Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol. 2009 May;131(2):360-5. doi: 10.1016/j.clim.2008.12.005. Epub 2009 Feb 4. PubMed PMID: 19195932.

49: European Group on Graves’ Orbitopathy (EUGOGO), Mourits MP, Bijl H, Altea MA, Baldeschi L, Boboridis K, Currò N, Dickinson AJ, Eckstein A, Freidel M, Guastella C, Kahaly GJ, Kalmann R, Krassas GE, Lane CM, Lareida J, Marcocci C, Marino M, Nardi M, Mohr Ch, Neoh C, Pinchera A, Orgiazzi J, Pitz S, Saeed P, Salvi M, Sellari-Franceschini S, Stahl M, von Arx G, Wiersinga WM. Outcome of orbital decompression for disfiguring proptosis in patients with Graves’ orbitopathy using various surgical procedures. Br J Ophthalmol. 2009 Nov;93(11):1518-23. doi: 10.1136/bjo.2008.149302. Epub 2008 Nov 21. PubMed PMID: 19028743.

50: Salvi M, Vannucchi G, Campi I, Currò N, Beck-Peccoz P. New immunomodulators in the treatment of Graves’ ophthalmopathy. Ann Endocrinol (Paris). 2008 Apr;69(2):153-6. doi: 10.1016/j.ando.2008.02.013. Epub 2008 Apr 15. PubMed PMID: 18417090.

51: Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008 Mar;18(3):333-46. doi: 10.1089/thy.2007.0315. PubMed PMID: 18341379.

52: Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008 Mar;158(3):273-85. doi: 10.1530/EJE-07-0666. PubMed PMID: 18299459.

53: Bonara P, Vannucchi G, Campi I, Rossi S, Cantoni F, Frugoni C, Sbrozzi F, Guastella C, Avignone S, Beck-Peccoz P, Salvi M. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves’ ophthalmopathy. Clin Rev Allergy Immunol. 2008 Feb;34(1):118-23. doi: 10.1007/s12016-007-8024-3. PubMed PMID: 18270865.

54: Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007 Jan;156(1):33-40. PubMed PMID: 17218723.

55: Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R, Beck-Peccoz P. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006 Apr;154(4):511-7. PubMed PMID: 16556712.

56: Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S, Beck-Peccoz P. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto’s thyroiditis: case report. Thyroid. 2004 Aug;14(8):631-4. PubMed PMID: 15320978.

57: Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves’ ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest. 2004 Mar;27(3):221-9. Review. PubMed PMID: 15164997.

58: Salvi M, Dazzi D, Pellistri I, Neri F, Wall JR. Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network. Ophthalmology. 2002 Sep;109(9):1703-8. PubMed PMID: 12208720.

59: Salvi M, Dazzi D, Pellistri I, Neri F. Prediction of the progression of thyroid-associated ophthalmopathy at first ophthalmologic examination: use of a neural network. Thyroid. 2002 Mar;12(3):233-6. PubMed PMID: 11952045.

60: Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med. 2001 Apr;18(4):329-32. PubMed PMID: 11437866.

61: Roti E, Minelli R, Salvi M. Thyroid hormone metabolism in obesity. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S113-5. Review. PubMed PMID: 10997624.

62: Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol. 2000 Aug;143(2):197-202. PubMed PMID: 10913938.

63: Salvi M, Spaggiari E, Neri F, Minelli R, Roti E. Expulsion of an artificial eye in a patient with thyroid-associated ophthalmopathy and surgical anophthalmos. Am J Med. 1999 Aug;107(2):191-2. PubMed PMID: 10460062.

64: Minelli R, Braverman LE, Valli MA, Schianchi C, Pedrazzoni M, Fiaccadori F, Salvi M, Magotti MG, Roti E. Recombinant interferon alpha (rIFN-alpha) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Clin Endocrinol (Oxf). 1999 Jan;50(1):95-100. PubMed PMID: 10341861.

65: Roti E, Gardini E, Magotti MG, Pilla S, Minelli R, Salvi M, Monica C, Maestri D, Cencetti S, Braverman LE. Are thyroid function tests too frequently and inappropriately requested? J Endocrinol Invest. 1999 Mar;22(3):184-90. PubMed PMID: 10219885.

66: Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B, Ackrell BA, Salvi M, Bellastella A, Bizzarro A, Sinisi AA, Wall JR. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999 Apr;84(4):1255-62. PubMed PMID: 10199764.

67: Gunji K, Kubota S, Swanson J, Kiljanski J, Bednarczuk T, Wengrowicz S, Salvi M, Wall JR. Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens. Thyroid. 1998 Jun;8(6):553-6. Review. Erratum in: Thyroid 1998 Nov;8(11):1079. PubMed PMID: 9669297.

68: Minelli R, Braverman LE, Giuberti T, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Roti E. Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. Clin Endocrinol (Oxf). 1997 Sep;47(3):357-61. PubMed PMID: 9373459.

69: Salvi M, Spaggiari E, Neri F, Macaluso C, Gardini E, Ferrozzi F, Minelli R, Wall JR, Roti E. The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement. J Clin Endocrinol Metab. 1997 Apr;82(4):1027-30. PubMed PMID: 9100568.

70: Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996 Nov;101(5):482-7. PubMed PMID: 8948271.

71: Minelli R, Girasole G, Pedrazzoni M, Giuliani N, Schianchi C, Giuberti T, Braverman LE, Salvi M, Roti E. Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy. J Investig Med. 1996 Aug;44(6):370-4. PubMed PMID: 8795300.

72: Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab. 1996 Aug;81(8):2976-9. PubMed PMID: 8768861.

73: Roti E, Minelli R, Salvi M. Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. J Clin Endocrinol Metab. 1996 May;81(5):1679-82. Review. PubMed PMID: 8626813.

74: Wall JR, Hayes M, Scalise D, Stolarski C, Nebes V, Kiljanski J, Salvi M, Sato M. Native gel electrophoresis and isoelectric focusing of a 64-kilodalton eye muscle protein shows that it is an important target for serum autoantibodies in patients with thyroid-associated ophthalmopathy and not expressed in other skeletal muscle. J Clin Endocrinol Metab. 1995 Apr;80(4):1226-32. PubMed PMID: 7714092.

75: Salvi M, Scalise D, Stolarski C, Arthurs B, Lindley S, Kennerdell J, Wall JR. Upper eyelid retraction in the absence of other evidence for progressive ophthalmopathy is associated with eye muscle autoantibodies. Clin Immunol Immunopathol. 1995 Jan;74(1):44-50. PubMed PMID: 7994926.

76: Salvi M, De Chiara F, Gardini E, Minelli R, Bianconi L, Alinovi A, Ricci R, Neri F, Tosi C, Roti E. Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. Eur J Endocrinol. 1994 Aug;131(2):113-9. PubMed PMID: 8075779.

77: Roti E, Bianconi L, De Chiara F, Minelli R, Tosi C, Gardini E, Salvi M, Braverman LE. Thyroid ultrasonography in patients with a previous episode of amiodarone induced thyrotoxicosis. J Endocrinol Invest. 1994 Apr;17(4):259-62. PubMed PMID: 7930377.

78: Roti E, Minelli R, Gardini E, Bianconi L, Salvi M, Gavaruzzi G, Ugolotti G, Braverman LE. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves’ disease. J Clin Endocrinol Metab. 1994 Mar;78(3):795-9. PubMed PMID: 8126159.

79: Boucher A, Bernard N, Miller A, Rodien P, Salvi M, Wall JR. Two dimensional gel electrophoresis identifies minor differences in immunologically cross-reactive 64 KDa autoantigens in the thyroid and eye muscle. J Endocrinol Invest. 1994 Jan;17(1):7-13. PubMed PMID: 8006329.

80: Salvi MG, Neri F. Thyroid ophthalmopathy. Curr Ther Endocrinol Metab. 1994;5:77-81. PubMed PMID: 7704806.

81: Wall JR, Triller H, Boucher A, Bernard NF, Salvi M, Ludgate M. Antibodies reactive with an intracellular epitope of a recombinant 64 kDa thyroid and eye muscle protein in patients with thyroid autoimmunity and ophthalmopathy. J Endocrinol Invest. 1993 Dec;16(11):863-8. PubMed PMID: 7511621.

82: Atabay C, Schrooyen M, Zhang ZG, Salvi M, Glinoer D, Wall JR. Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy. J Endocrinol Invest. 1993 Oct;16(9):669-74. PubMed PMID: 7904280.

83: Wall JR, Bernard N, Boucher A, Salvi M, Zhang ZG, Kennerdell J, Tyutyunikov A, Genovese C. Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves’ hyperthyroidism and Hashimoto’s thyroiditis. Clin Immunol Immunopathol. 1993 Jul;68(1):1-8. PubMed PMID: 8513588.

84: Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1993 Apr;76(4):928-32. PubMed PMID: 7682562.

85: Crock P, Salvi M, Miller A, Wall J, Guyda H. Detection of anti-pituitary autoantibodies by immunoblotting. J Immunol Methods. 1993 Jun 4;162(1):31-40. PubMed PMID: 8509651.

86: Boucher A, Bernard N, Zhang ZG, Rodien P, Salvi M, Wall JR. Nature of 64 kDa eye muscle and thyroid membrane proteins and their significance in thyroid-associated ophthalmopathy–an hypothesis. Autoimmunity. 1993;16(2):79-82. Review. PubMed PMID: 8180320.

87: Minelli R, Gardini E, Bianconi L, Salvi M, Roti E. Subclinical hypothyroidism, overt thyrotoxicosis and subclinical hypothyroidism: the subsequent phases of thyroid function in a patient chronically treated with amiodarone. J Endocrinol Invest. 1992 Dec;15(11):853-5. PubMed PMID: 1291598.

88: Zhang ZG, Salvi M, Miller A, Bernard N, Arthurs B, Wall JR. Restricted tissue reactivity of autoantibodies to a 64-kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. Clin Immunol Immunopathol. 1992 Feb;62(2):183-9. PubMed PMID: 1730156.

89: Cohen M, Salvi M, Miller A, Bernard N, Wall JR. Cell-mediated immunity to orbital tissue antigens in thyroid-associated ophthalmopathy determined using the leukocyte procoagulant activity assay. Autoimmunity. 1992;11(4):225-31. PubMed PMID: 1581466.

90: Zhang ZG, Dong Q, Rodien P, Alcalde L, Bernard N, Boucher A, Salvi M, Arthurs B, Vassart GM, Ludgate M, et al. Antibodies in the serum of patients with autoimmune thyroid disorders react with a recombinant 98 amino acid fragment of a full length 64 kDa eye muscle membrane protein which is also expressed in the thyroid. Autoimmunity. 1992;13(2):151-7. PubMed PMID: 1467436.

91: Miller A, Arthurs B, Boucher A, Liberman A, Bernard N, Rodien P, Salvi M, Wall JR. Significance of antibodies reactive with a 64 kDa eye muscle membrane antigen in patients with thyroid autoimmunity. Thyroid. 1992 Fall;2(3):197-202. PubMed PMID: 1422231.

92: Boucher A, Bernard NF, Zhang ZG, Salvi M, Rodien P, Triller H, Wall JR. Nature and significance of orbital autoantigens and their corresponding autoantibodies in thyroid-associated ophthalmopathy. Autoimmunity. 1992;13(1):89-93. Review. PubMed PMID: 1420811.

93: Bernard NF, Boucher A, Zhang ZG, Salvi M, Wall JR. Nature of a 64 kDa eye muscle membrane autoantigen as determined from immunoprecipitation and immunoblotting. Exp Clin Endocrinol. 1991 May;97(2-3):191-6. PubMed PMID: 1915633.

94: Wall JR, Salvi M, Bernard NF, Boucher A, Haegert D. Thyroid-associated ophthalmopathy–a model for the association of organ-specific autoimmune disorders. Immunol Today. 1991 May;12(5):150-3. Review. PubMed PMID: 1878126.

95: Teboul B, Triller H, Chung F, Bernard N, Zhang ZG, Wall JR, Salvi M. Muscle and species reactivity of mouse monoclonal antibodies to human eye muscle membrane antigens. Clin Immunol Immunopathol. 1991 Apr;59(1):104-16. PubMed PMID: 1826865.

96: Medeiros-Neto G, Zhang ZG, Lima N, Iacona A, Liberman A, Salvi M, Wall JR. Immunologically mediated cytotoxicity against human eye muscle and thyroid cells in euthyroid and thyrotoxic Graves’ ophthalmopathy. Autoimmunity. 1991;9(4):293-300. PubMed PMID: 1954309.

97: Salvi M, Bernard N, Miller A, Zhang ZG, Gardini E, Wall JR. Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. Thyroid. 1991 Summer;1(3):207-13. PubMed PMID: 1824337.

98: Fukazawa H, Hiromatsu Y, Bernard N, Salvi M, Wall JR. Binding of peripheral blood and thyroidal T lymphocytes to thyroid cell monolayers: possible role of “homing-like” receptors in the pathogenesis of thyroid autoimmunity. Autoimmunity. 1991;10(3):181-8. PubMed PMID: 1756223.

99: Bernard NF, Ertug F, Teboul N, Zhang ZG, Salvi M, Wall JR. Isotype and immunoglobulin subclass distribution of eye muscle membrane reactive antibodies in the serum of patients with thyroid-associated ophthalmopathy as detected in Western blotting. Autoimmunity. 1991;10(1):57-63. PubMed PMID: 1742423.

100: Roti E, Minelli R, Gardini E, Salvi M, Bianconi L, Balducci L, Manfredi A, Braverman LE. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis. J Endocrinol Invest. 1990 Jan;13(1):69-72. PubMed PMID: 2319110.

101: Salvi M, Zhang ZG, Haegert D, Woo M, Liberman A, Cadarso L, Wall JR. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab. 1990 Jan;70(1):89-94. PubMed PMID: 2294141.

102: Hiromatsu Y, Cadarso L, Salvi M, Wall JR. Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy. Autoimmunity. 1990;5(3):205-13. PubMed PMID: 2129753.

103: Kapusta M, Salvi M, Triller H, Gardini E, Bernard N, Wall JR. Eye muscle membrane reactive antibodies are not detected in the serum or immunoglobulin fraction of patients with thyroid-associated ophthalmopathy using an ELISA and crude membranes. Autoimmunity. 1990;7(1):33-40. PubMed PMID: 2103308.

104: Salvi M, Gardini E, Minelli R, Bianconi L, Pino S, Braverman LE, Roti E. Iodine deficiency in schoolchildren of the province of Parma, Italy. J Endocrinol Invest. 1989 Oct;12(9):651-2. PubMed PMID: 2584639.

105: Roti E, Gardini E, Minelli R, Salvi M, Robuschi G, Braverman LE. Methimazole and serum thyroid hormone concentrations in hyperthyroid patients: effects of single and multiple daily doses. Ann Intern Med. 1989 Jul 15;111(2):181-2. PubMed PMID: 2742250.

106: Salvi M, Hiromatsu Y, Bernard N, How J, Wall JR. Pathogenesis of thyroid-associated ophthalmopathy. Dev Ophthalmol. 1989;20:58-67. PubMed PMID: 2591628.

107: Dillon J, Zhang ZG, Hiromatsu N, Bernard M, Salvi M, Wall JR. Failure to detect complement-mediated antibody-dependent cytotoxicity against human orbital tissue cells in the serum of patients with thyroid-associated ophthalmopathy. Autoimmunity. 1989;5(1-2):125-32. PubMed PMID: 2519012.

108: Salvi M, Fukazawa H, Bernard N, Hiromatsu Y, How J, Wall JR. Role of autoantibodies in the pathogenesis and association of endocrine autoimmune disorders. Endocr Rev. 1988 Nov;9(4):450-66. Review. PubMed PMID: 3065074.

109: Hiromatsu Y, Fukazawa H, Guinard F, Salvi M, How J, Wall JR. A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1988 Sep;67(3):565-70. PubMed PMID: 3410941.

110: Roti E, Montermini M, Roti S, Gardini E, Robuschi G, Minelli R, Salvi M, Bentivoglio M, Guiducci U, Braverman LE. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med. 1988 Sep;148(9):1919-21. PubMed PMID: 2458079.

111: Salvi M, Miller A, Wall JR. Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid-associated ophthalmopathy. FEBS Lett. 1988 May 9;232(1):135-9. PubMed PMID: 3366241.

112: Salvi M, Bingoye F, Chung F, Wall JR. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1988 May;66(5):939-45. PubMed PMID: 3360902.

113: Coiro V, Roti E, d’Amato L, Alboni A, Gardini E, Salvi M, Cersosimo G, Bianconi L, Zanardi G, Bacchi-Modena A, et al. Effect of bromocriptine on neurophysin secretion in pregnant women in labour. Gynecol Endocrinol. 1988 Mar;2(1):35-43. PubMed PMID: 3177010.

114: Roti E, Robuschi G, Gardini E, Montermini M, Salvi M, Manfredi A, Gnudi A, Braverman LE. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves’ disease. Clin Endocrinol (Oxf). 1988 Mar;28(3):305-14. PubMed PMID: 3168311.

115: Gardini E, Robuschi G, Salvi M, Montermini M, Minelli R, Bentivoglio M, Chiodera P, Roti E. Insulin and C-peptide responses to oral glucose load in hypothyroid patients. Diabete Metab. 1988 Mar-Apr;14(2):139-41. PubMed PMID: 3042489.

116: Salvi M, How J. Pregnancy and autoimmune thyroid disease. Endocrinol Metab Clin North Am. 1987 Jun;16(2):431-44. Review. PubMed PMID: 3319591.

117: Robuschi G, Montermini M, Chiodera P, Gardini E, Salvi M, Alboni A, Borciani E, Gnudi A, Roti E. Dopaminergic regulation of fetal growth hormone (GH) secretion: study with maternal administration of bromocriptine. J Perinat Med. 1987;15(4):345-9. PubMed PMID: 3437376.

118: Miller A, Sikorska H, Salvi M, Wall JR. Evaluation of an enzyme-linked immunosorbent assay for the measurement of autoantibodies against eye muscle membrane antigens in Graves’ ophthalmopathy. Acta Endocrinol (Copenh). 1986 Dec;113(4):514-22. PubMed PMID: 3788421.

119: Robuschi G, Montermini M, Gardini E, Salvi M, Braverman LE, Gnudi A, Roti E. Unusual association of medullary carcinoma and toxic adenoma of the thyroid. J Nucl Med Allied Sci. 1986 Oct-Dec;30(4):231-4. PubMed PMID: 3585511.

120: Roti E, Gardini E, D’Amato L, Salvi M, Robuschi G, Manfredi A, Dallara G, Pino S, Guazzi AM, Gnudi A, et al. Goiter size and thyroid function in an endemic goiter area in northern Italy. J Clin Endocrinol Metab. 1986 Sep;63(3):558-63. PubMed PMID: 3090091.

121: Robuschi G, Manfredi A, Salvi M, Gardini E, Montermini M, d’Amato L, Borciani E, Negrotti L, Gnudi A, Roti E. Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves’ disease. J Endocrinol Invest. 1986 Aug;9(4):287-91. PubMed PMID: 3537101.

122: Salvi M, Ferrari C, d’Amato L, Gardini E, Robuschi G, Gnudi A, Roti E. Thyroid function in patients with chronic active hepatitis. Minerva Endocrinol. 1986 Jul-Sep;11(3):163-7. PubMed PMID: 3796562.

123: Roti E, Robuschi G, Alboni A, d’Amato L, Montermini M, Gardini E, Salvi M, Borciani E, Dall’Aglio E, Bisi S, et al. Human foetal prolactin but not thyrotropin secretion is decreased by bromocriptine. Acta Endocrinol (Copenh). 1986 May;112(1):35-42. PubMed PMID: 3716756.

124: Roti E, Braverman LE, Robuschi G, Salvi M, Gardini E, d’Amato L, Maestri D, Montermini M, Borciani E, Pezzarossa A, et al. Basal and glucose- and arginine-stimulated serum concentrations of insulin, C-peptide, and glucagon in hyperthyroid patients. Metabolism. 1986 Apr;35(4):337-42. PubMed PMID: 3515118.

125: Robuschi G, Medici D, Fesani F, Barboso G, Montermini M, d’Amato L, Gardini E, Borciani E, Dall’Aglio E, Salvi M, et al. Cardiopulmonary bypass: a low T4 and T3 syndrome with blunted thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH). Horm Res. 1986;23(3):151-8. PubMed PMID: 3081419.

126: Roti E, Robuschi G, Manfredi A, D’Amato L, Gardini E, Salvi M, Montermini M, Barlli AL, Gnudi A, Braverman LE. Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves’ disease. Clin Endocrinol (Oxf). 1985 Apr;22(4):489-96. PubMed PMID: 3838710.

127: Robuschi G, d’Amato L, Salvi M, Gardini E, Montermini M, Dall’Aglio E,Borciani E, Fontanesi V, Alboni A, Gnudi A, et al. Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus. J Endocrinol Invest. 1984 Oct;7(5):521-4. PubMed PMID: 6150957.

128: Roti E, Robuschi G, Alboni A, Emanuele R, d’Amato L, Gardini E, Salvi M, Dall’Aglio E, Gnudi A, Braverman LE. Inhibition of foetal growth hormone (GH) and thyrotrophin (TSH) secretion after maternal administration of somatostatin. Acta Endocrinol (Copenh). 1984 Jul;106(3):393-9. PubMed PMID: 6146235.

129: Coiro V, Chiodera P, Rossi G, Volpi R, Salvi M, Camellini L, Roti E. Effect of naloxone on oxytocin-induced cortisol decrease in normal men. Acta Endocrinol (Copenh). 1985 Feb;108(2):261-5. PubMed PMID: 2982243.

130: Robuschi G, Emanuele R, d’Amato L, Salvi M, Montermini M, Gnudi A, Roti E. Failure of metoclopramide to release GH in pregnant women. Horm Metab Res. 1983 Sep;15(9):460-1. PubMed PMID: 6642419.

131: Robuschi G, Emanuele R, d’Amato L, Salvi M, Dall’Aglio E, Gardini E, Fatone M, Foscolo S, Gnudi A, Roti E. Effect of metoclopramide on maternal and fetal hyperprolactinemia. J Endocrinol Invest. 1983 Apr;6(2):107-11. PubMed PMID: 6863847.

132: Volpi R, Coiro V, Salvi M, Pelosi G, Mancini P, Chiodera P. Effect of metoclopramide on serum growth hormone levels in cirrhotic men. J Endocrinol Invest. 1983 Apr;6(2):101-5. PubMed PMID: 6863846.

133: Emanuele R, Robuschi G, Tagliaferri A, D’Amato L, Salvi M, Gnudi A, Manfredi A, Tecchio T, Roti E. Iodothyronine and thyrotropin concentrations after iodoamide administration for angiographic studies. Ric Clin Lab. 1982 Oct-Dec;12(4):589-94. PubMed PMID: 7156708.